Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 93 for “"lapatinib"”.

  1. Defining the Relationship between the Bioactivation of Lapatinib by CYP3A and Lapatinib-Induced Hepatotoxicity

    Lapatinib was the first orally active dual tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR, ErbB1) and human epidermal receptor 2 (HER2, ErbB2) to be approved by the US Food and Drug Administration (FDA). In 2008, the FDA issued a black-box warning for lapatinib …

    washington Repository record for Defining the Relationship between the Bioactivation of Lapatinib by CYP3A and Lapatinib-Induced Hepatotoxicity (opens in a new tab)

  2. Understanding Acquired Resistance to Lapatinib In Breast Cancer Cells

    … often over-expressed in human breast carcinomas. Lapatinib is an ErbB1 and ErbB2 tyrosine kinase inhibitor that has been shown to have anti-proliferative effects in breast and lung cancer cells. Cells treated with Lapatinib undergo G1 phase arrest, followed by apoptosis. Lapatinib has been …

    uthsc Repository record for Understanding Acquired Resistance to Lapatinib In Breast Cancer Cells (opens in a new tab)

  3. Response and resistance to lapatinib in HER2-overexpressing breast cancer

    … has been implicated in breast cancer. Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor used in advanced HER2-positive breast cancer patients who have previously progressed on trastuzumab treatment. Recent meta-analysis of several clinical trials showed that lapatinib was inferior …

    oxford Repository record for Response and resistance to lapatinib in HER2-overexpressing breast cancer (opens in a new tab)

  4. Mechanisms of resistance to lapatinib in HER2 positive breast cancer

    Lapatinib is a tyrosine kinase inhibitor of HER2 which blocks downstream signaling pathways in HER2 positive breast cancer cell lines, tumor xenografts and HER2 positive breast cancer patients. However, pre-clinical and clinical studies have shown that HER2 positive patients can exhibit either …

    dcu Download PDF for Mechanisms of resistance to lapatinib in HER2 positive breast cancer (opens in a new tab)

  5. Measuring Single Cell Responses to Lapatinib In A Heterogeneous Population

    … to anti- EGFR/ErbB2 therapy in breast cancer to Lapatinib [1]. However, one the of the very important unanswered questions at the cellular and molecular level is the mechanismsthatleadstoselection of cells that are resistant to Lapatinib whereby there exists two possibilities: 1. Cells are …

    uthsc Repository record for Measuring Single Cell Responses to Lapatinib In A Heterogeneous Population (opens in a new tab)

  6. Pi3K- and Mtor-Dependent Mechanisms of Lapatinib Resistance and Resulting Therapeutic Opportunities

    … responsive to the HER2 kinase inhibitor lapatinib, but generally for only short duration. We aimed to understand how breast cancers with HER2 amplification become resistant to lapatinib, in order to identify potential therapies that can overcome lapatinib resistance. To establish …

    uthsc Repository record for Pi3K- and Mtor-Dependent Mechanisms of Lapatinib Resistance and Resulting Therapeutic Opportunities (opens in a new tab)

  7. Lapatinib and Sorafenib Kill GBM Tumor Cells in a Greater than Additive Manner

    … sorafenib, an oral multi kinase inhibitor, and lapatinib, an epidermal growth factor receptor (EGFR) inhibitor, used in combination have been shown to kill GBM cells be through inhibition of major growth mediating signaling pathways that are frequently over expressed in gliomas, including …

    vcu Repository record for Lapatinib and Sorafenib Kill GBM Tumor Cells in a Greater than Additive Manner (opens in a new tab)

  8. In vitro and in vivo models to assess the mechanism of lapatinib-induced diarrhoea

    Lapatinib, an ErbB1/ErbB2 tyrosine kinase inhibitor is effective in breast cancer treatment but is associated with diarrhoea. ErbB1 inhibition by lapatinib may interfere with the normal functioning in the intestines. However, the underlying mechanisms remain unclear. This PhD project was conducted …

    adelaide Repository record for In vitro and in vivo models to assess the mechanism of lapatinib-induced diarrhoea (opens in a new tab)

  9. The Ontogeny and Vulnerability of Lapatinib Drug Tolerant Persisters in HER2-positive Breast Cancer

    … cancer cell lines can give rise to DTPs after lapatinib treatment. Lapatinib DTPs showed re-wiring of the PI3K/AKT/mTORC1 pathway, such that they are more dependent on PI3K than AKT for mTORC1 activation and survival. One AKT-independent survival pathway was mediated through the transcriptional …

    toronto-retro Repository record for The Ontogeny and Vulnerability of Lapatinib Drug Tolerant Persisters in HER2-positive Breast Cancer (opens in a new tab)

  10. Siramesine and lapatinib induce synergic cell death via a ferroptotic mechanism in lung adenocarcinoma and glioblastoma cells

    … of siramesine, a lysosome disruptor, and lapatinib, a dual tyrosine kinase inhibitor (TKI), synergistically induced death in breast cancer cells. This cell death had characteristics of ferroptosis: it was blocked by the ferroptosis inhibitor ferrostatin-1 and the iron chelator …

    manitoba Repository record for Siramesine and lapatinib induce synergic cell death via a ferroptotic mechanism in lung adenocarcinoma and glioblastoma cells (opens in a new tab)

  11. The lysosomotropic agent siramesine and the tyrosine kinase inhibitor lapatinib induce cell death in prostate cancer cells

    … siramesine and the tyrosine kinase inhibitor lapatinib to be the most potent drug combination to induce cell death. I also investigated the mechanism by which cells were dying by siramesine and lapatinib treatment and found that increases in ROS caused significant cellular damage leading to …

    manitoba Repository record for The lysosomotropic agent siramesine and the tyrosine kinase inhibitor lapatinib induce cell death in prostate cancer cells (opens in a new tab)

  12. Desenvolvimento farmacotécnico de nanocápsulas multiparede contendo ditosilato de lapatinib e complexadas com metal para funcionalização de superfície

    … do receptor da tirosina–quinase, ditosilato de lapatinib. Nesse sentido, o trabalho está centrado no desenvolvimento farmacotécnico e caracterização físico-química de nanocápsulas multiparede revestidas com polissorbato 80 e fosfatidilcolina (LIPOID S75®), seguidas de revestimento com quitosana, …

    brazil-ufrgs Repository record for Desenvolvimento farmacotécnico de nanocápsulas multiparede contendo ditosilato de lapatinib e complexadas com metal para funcionalização de superfície (opens in a new tab)

  13. Hyaluronic Acid Coated Targeted Lipid Micellar Nanoparticle as a Delivery Vehicle for Lapatinib and Ketoconazole in EGFR mutated Lung Cancer

    … mainly occur in TP53, EGFR, and KRAS genes. Lapatinib is a small molecule tyrosine kinase inhibitor which acts reversibly on both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Overexpression of EGFR leads to increased production and signaling of …

    usf Repository record for Hyaluronic Acid Coated Targeted Lipid Micellar Nanoparticle as a Delivery Vehicle for Lapatinib and Ketoconazole in EGFR mutated Lung Cancer (opens in a new tab)

  14. Development of Novel Peptide-Drug Conjugates for Targeting Brain Tumors and Brain Metastases

    … delivery of effective therapeutics to brain. Lapatinib is an orally administered HER-2 tyrosine kinase inhibitor and has shown the potential for improving the outcomes of HER2+ breast cancer brain metastases. Irinotecan is the prodrug of anticancer drug SN-38 which stabilizes the topoisomerase …

    houston Repository record for Development of Novel Peptide-Drug Conjugates for Targeting Brain Tumors and Brain Metastases (opens in a new tab)

  15. Novel mechanisms of HER2-targeted therapy resistance in breast cancer

    … develop strategies to overcome resistance. Two lapatinib resistant cell lines (SKBR3-L and HCC1954-L) previously generated in our lab showed increased protein phosphatase 2A (PP2A) activity. In this study, the resistant cell lines were more sensitive to PP2A inhibition by okadaic acid and the …

    dcu Download PDF for Novel mechanisms of HER2-targeted therapy resistance in breast cancer (opens in a new tab)

  16. The covalent JNK inhibitor, JNK-in-8, synergizes with lapatinib to cause cell death in basal-like breast cancer cell lines

    … when combined with the EGFR/HER2 inhibitor lapatinib (Tykerb™). Treatment with the covalent JNK inhibitor, JNK-IN-8, synergizes with lapatinib to cause cell death, while these drugs as single agents have little effect on cell viability. Our studies suggest that JNK1 and HER2 are the key …

    texas Repository record for The covalent JNK inhibitor, JNK-in-8, synergizes with lapatinib to cause cell death in basal-like breast cancer cell lines (opens in a new tab)

  17. The mechanisms of pro-survival action of NRG1 in brain metastatic HER2+ breast cancer cells

    … small molecule tyrosine kinase inhibitor Lapatinib. NRG1 mitigated cytotoxicity induced by Lapatinib, as shown by higher viability in WST-1 assays and the preserved ability for long-term cell propagation in clonogenicity assays. NRG-1 blocked Lapatinib-driven PARP cleavage and activation …

    manitoba Repository record for The mechanisms of pro-survival action of NRG1 in brain metastatic HER2+ breast cancer cells (opens in a new tab)

  18. The role of miRNAs in resistance to HER2 targeted therapies

    Trastuzumab, a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor are approved treatments for HER2 positive breast cancer; however, patients that initially respond frequently develop resistance. The aims of this study were to investigate microRNA expression in acquired and/or innate …

    dcu Download PDF for The role of miRNAs in resistance to HER2 targeted therapies (opens in a new tab)

Page 1 of 5